JP7229541B2 - 脊椎融合手術後の非融合を予測するためのバイオマーカーとしてのcd8t細胞サブセット - Google Patents
脊椎融合手術後の非融合を予測するためのバイオマーカーとしてのcd8t細胞サブセット Download PDFInfo
- Publication number
- JP7229541B2 JP7229541B2 JP2019565847A JP2019565847A JP7229541B2 JP 7229541 B2 JP7229541 B2 JP 7229541B2 JP 2019565847 A JP2019565847 A JP 2019565847A JP 2019565847 A JP2019565847 A JP 2019565847A JP 7229541 B2 JP7229541 B2 JP 7229541B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- fusion
- sample
- spinal fusion
- surgery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
-患者からの試料中の細胞集団の頻度を決定するための装置、
-プログラムされたマイクロプロセッサ、
プログラムされたマイクロプロセッサは、本発明の上記態様又は実施形態に記載の方法を実行するように構成される。
椎間領域における瘢痕組織形成の存在に基づく少なくとも術後24週後の不完全な椎体融合。(イトウゼンヤら、SPINE Volume 35,Number 21,ppE1 101 -E1 105;2010)
1)2つの椎体を接続する骨梁の架橋がない
2)5度を超える角運動
3)3ミリメートルを超える矢状方向移動
4)ダボと宿主の椎骨終板との間の境界面の半分以上を含む放射線透過性
Claims (8)
- 非融合を有する又は発症する確率を予測するための方法であって、脊椎融合手術を受ける前又は脊椎融合手術後であり、前記方法は、患者から得られた試料中においてCD8+CD57+、CD8+CD28-及びCD8+CD57+CD28-から選択されるCD8+T細胞の亜集団の頻度を決定することを含み、
- 骨融合後の正常融合を有する大集団について決定された標準値と比較した場合に、試料が前記CD8+T細胞の亜集団が少なくとも2倍高い頻度を示す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測され、及び/又は、
- 試料が、試料中のすべてのCD8+細胞の合計の少なくとも22.7%のCD8+CD57+CD28-細胞の画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測され、及び/又は、
- 試料が、試料中のすべてのCD8+細胞の合計の少なくとも85.6%のCD8+CD57+細胞及びCD8+CD28-細胞の合計画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測され、及び/又は、
- 試料が、試料中のすべてのCD8+細胞の合計の少なくとも24.4%のCD8+CD57+細胞の画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測され、及び/又は、
- 試料が、試料中のすべてのCD8+細胞の合計の少なくとも28.0%のCD8+CD28-細胞の画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測される、
前記方法。 - - 試料が、試料中のすべてのCD8+細胞の合計の少なくとも33.1%のCD8+CD57+CD28-細胞の画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測され、及び/又は、
- 試料が、試料中のすべてのCD8+細胞の合計の少なくとも37.6%のCD8+CD57+細胞の画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測され、及び/又は、
- 試料が、試料中のすべてのCD8+細胞の合計の少なくとも42.9%のCD8+CD28-細胞の画分を表す場合は、患者が脊椎融合手術後に非融合を有する又は発症する高い確率を有すると予測される、請求項1に記載の方法。 - 前記非融合が、骨組織によって自然に接続されていない2つ以上の骨又は骨片間の非融合である、請求項1又は2に記載の方法。
- 前記非融合が、2つ以上の椎骨間の非融合である、請求項3に記載の方法。
- 前記試料が血液試料である、請求項1~4のいずれか一項に記載の方法。
- 前記試料が前記患者から脊椎融合手術前、脊椎融合手術中又は脊椎融合手術後に得られた試料である、請求項1~5のいずれか一項に記載の方法。
- 脊椎融合手術を受ける前又は脊椎融合手術後に、非融合を有する又は発症する確率を予測するためのシステムであって、
- 患者から得られた試料中の細胞集団の頻度を決定する装置
- プログラムされたマイクロプロセッサを含み、
前記マイクロプロセッサは、請求項1~6のいずれか一項に記載の方法を実行するように構成される、
前記システム。 - 請求項1~6のいずれか一項に記載の方法における抗体の組み合わせの使用であって、脊椎融合手術を受ける前又は脊椎融合手術後であり、前記組み合わせが抗CD8抗体及び抗CD57抗体、又は抗CD8抗体及び抗CD28抗体、又は抗CD8抗体、抗CD28抗体及び抗CD57抗体を含み、かつ前記抗体は蛍光に基づくフローサイトメトリーに適している、前記使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17173320 | 2017-05-29 | ||
EP17173320.7 | 2017-05-29 | ||
EP17206698.7 | 2017-12-12 | ||
EP17206698.7A EP3499236A1 (en) | 2017-12-12 | 2017-12-12 | Cd8 t cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery |
PCT/EP2018/064085 WO2018219959A1 (en) | 2017-05-29 | 2018-05-29 | Cd8 t cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020521976A JP2020521976A (ja) | 2020-07-27 |
JP7229541B2 true JP7229541B2 (ja) | 2023-02-28 |
Family
ID=62200471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019565847A Active JP7229541B2 (ja) | 2017-05-29 | 2018-05-29 | 脊椎融合手術後の非融合を予測するためのバイオマーカーとしてのcd8t細胞サブセット |
Country Status (5)
Country | Link |
---|---|
US (1) | US11802873B2 (ja) |
EP (1) | EP3631450B1 (ja) |
JP (1) | JP7229541B2 (ja) |
CN (1) | CN110945358B (ja) |
WO (1) | WO2018219959A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022520139A (ja) | 2018-10-12 | 2022-03-29 | セラダプティブ インク | β-リン酸三カルシウム結合配列を含むポリペプチドとその使用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080019969A1 (en) | 2006-07-07 | 2008-01-24 | Gorman James R | Methods for Preventing, Postponing or Improving the Outcome of Invasive Spinal Procedures |
JP2015507197A (ja) | 2012-02-03 | 2015-03-05 | シャリテ−ウニヴェルズィテートメディツィーン ベルリン | 骨折治癒の遅延を予測するマーカーとしてのcd8+t細胞サブセット |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5492697A (en) | 1990-03-05 | 1996-02-20 | Board Of Regents, Univ. Of Texas System | Biodegradable implant for fracture nonunions |
AU2007275654A1 (en) * | 2006-07-19 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | WSX-1/p28 as a target for anti-inflammatory responses |
WO2011028257A1 (en) * | 2009-08-24 | 2011-03-10 | The Trustees Of Columbia University In The City Of New York | Assay for determining health of cd8+ t cells |
RU2012152828A (ru) * | 2010-05-07 | 2014-06-20 | Бейлор Рисёч Инститьют | Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека |
CA2827894A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
EP3185885B1 (en) * | 2014-08-26 | 2020-08-19 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
-
2018
- 2018-05-29 JP JP2019565847A patent/JP7229541B2/ja active Active
- 2018-05-29 CN CN201880048733.9A patent/CN110945358B/zh active Active
- 2018-05-29 US US16/618,118 patent/US11802873B2/en active Active
- 2018-05-29 EP EP18725881.9A patent/EP3631450B1/en active Active
- 2018-05-29 WO PCT/EP2018/064085 patent/WO2018219959A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080019969A1 (en) | 2006-07-07 | 2008-01-24 | Gorman James R | Methods for Preventing, Postponing or Improving the Outcome of Invasive Spinal Procedures |
JP2015507197A (ja) | 2012-02-03 | 2015-03-05 | シャリテ−ウニヴェルズィテートメディツィーン ベルリン | 骨折治癒の遅延を予測するマーカーとしてのcd8+t細胞サブセット |
Non-Patent Citations (1)
Title |
---|
AXELRAD T W; ET AL,BONE MORPHOGENETIC PROTEINS IN ORTHOPAEDIC SURGERY,CYTOKINE AND GROWTH FACTOR REVIEWS,英国,ELSEVIER LTD,2009年10月,VOL:20, NR:5-6,PAGE(S):481 - 488 |
Also Published As
Publication number | Publication date |
---|---|
WO2018219959A1 (en) | 2018-12-06 |
EP3631450A1 (en) | 2020-04-08 |
CN110945358A (zh) | 2020-03-31 |
EP3631450B1 (en) | 2022-11-23 |
CN110945358B (zh) | 2023-07-25 |
JP2020521976A (ja) | 2020-07-27 |
US11802873B2 (en) | 2023-10-31 |
US20200182872A1 (en) | 2020-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Belasco et al. | Psoriatic arthritis: what is happening at the joint? | |
Maksymowych | Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy | |
Harre et al. | Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin | |
Hansson et al. | Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides | |
EP1882946B1 (en) | Method of assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 | |
Decramer et al. | Non-invasive markers of ureteropelvic junction obstruction | |
Clunie et al. | Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features? | |
Chen et al. | Upregulation of BMP-2 expression in peripheral blood mononuclear cells by proinflammatory cytokines and radiographic progression in ankylosing spondylitis | |
Park et al. | Proteomics in rheumatoid arthritis research | |
Visvanathan et al. | Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study | |
EP1721162A1 (en) | Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a | |
JP2018035157A (ja) | 骨折治癒の遅延を予測するマーカーとしてのcd8+t細胞サブセット | |
Jonsson et al. | The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy | |
JP7229541B2 (ja) | 脊椎融合手術後の非融合を予測するためのバイオマーカーとしてのcd8t細胞サブセット | |
Sato et al. | Ossification of the posterior longitudinal ligament of the cervical spine: histopathological findings around the calcification and ossification front | |
Zhang et al. | Moderate mechanical stimulation rescues degenerative annulus fibrosus by suppressing caveolin-1 mediated pro-inflammatory signaling pathway | |
Witte et al. | IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis | |
Dusad et al. | Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant | |
Mori et al. | Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies | |
Caparbo et al. | Monocytes from male patients with ankylosing spondylitis display decreased osteoclastogenesis and decreased RANKL/OPG ratio | |
Ahmed et al. | Deficient cytokine control modulates temporomandibular joint pain in rheumatoid arthritis | |
Maksymowych | Biomarkers in spondyloarthritis | |
Bresnihan et al. | Synovial tissue analysis in clinical trials. | |
EP3499236A1 (en) | Cd8 t cell subsets as a biomarker for predicting non-fusion after spinal fusion surgery | |
Maksymowych et al. | Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210520 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220906 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221025 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7229541 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |